FDA Brief

Warning letters Drugs

FDA warning letter to

PolleyMed, LLC

High riskIssued May 14Posted May 19Center for Drug Evaluation and Research (CDER)

FDA says PolleyMed's SaniiSwab nasal swab is an unapproved, misbranded drug sold online with infection-prevention claims and a false FDA approval claim.

What happened

FDA found the problems by reviewing PolleyMed's product labeling, its website www.saniiswab.com, and its Facebook and Instagram pages in April 2026. The review found SaniiSwab marketed without a prescription as a two-step nasal cleaner that fights germs, with claims about staph, MRSA, flu, RSV, COVID-19 and hospital-acquired infections. One page also stated "FDA OTC approved," which FDA says is false.

What FDA found

  1. The labeling says the product cleans and sanitizes the inside of the nose to help prevent infection, which makes it a drug in FDA's view.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. It is a new drug sold without an FDA-approved application, and no approved application exists for it.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  3. It is not generally recognized as safe and effective for its labeled use, and the over-the-counter monograph for first aid antiseptics does not allow use inside the nostrils.

    FD&C Act section 201(p), 21 U.S.C. 321(p); OTC Monograph M003
  4. Claims that it prevents infection from airborne pathogens and from COVID-19 and influenza go far beyond any permitted over-the-counter monograph claim.

    OTC Monograph M003; 1994 Tentative Final Monograph, 59 FR 31402
  5. The website wrongly says the product is "FDA OTC approved," which makes it misbranded (a drug with false or misleading labeling).

    FD&C Act section 502(a), 21 U.S.C. 352(a); 21 CFR 207.77(b)
  6. Shipping this unapproved and misbranded drug across state lines is prohibited.

    FD&C Act sections 301(a) and 301(d), 21 U.S.C. 331(a) and 331(d)

What FDA wants

FDA tells the company to investigate the root causes, correct the violations, and explain how it will prevent them from recurring. The written response and supporting documents are due to FDAAdvisory@fda.hhs.gov within 15 business days, with reference number 726018 in the subject line.

Who should pay attention

  • companies selling over-the-counter drug products directly to consumers online
  • contract manufacturers and brands making nasal or antiseptic products
  • retailers and distributors that carry unapproved drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk